{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:38:27Z","timestamp":1791509907420,"version":"4.3.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003748","name":"Svenska S\u00e4llskapet f\u00f6r Medicinsk Forskning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020948","name":"AstraZeneca M\u00f6lndal","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Natriuretic peptides (NPs) are cardio-derived hormones that have a crucial role in maintaining cardiovascular homeostasis. Physiological effects of NPs are mediated by binding to natriuretic peptide receptors 1 and 2 (NPR1\/2), whereas natriuretic peptide receptor 3 (NPR3) acts as a clearance receptor that removes NPs from the circulation. Mouse studies have shown that local NP-signaling in the kidney glomerulus is important for the maintenance of renal homeostasis. In this study we examined the expression of NPR3 in kidney tissue and explored its involvement in renal physiology and disease by generating podocyte-specific knockout mice (<jats:italic>NPR3<\/jats:italic><jats:sup><jats:italic>podKO<\/jats:italic><\/jats:sup>) as well as by using an NPR3 inhibitor (NPR3i) in rodent models of kidney disease. NPR3 was highly expressed by podocytes. <jats:italic>NPR3<\/jats:italic><jats:sup><jats:italic>podKO<\/jats:italic><\/jats:sup> animals showed no renal abnormalities under healthy conditions and responded similarly to nephrotoxic serum (NTS) induced glomerular injury. However, NPR3i showed reno-protective effects in the NTS-induced model evidenced by decreased glomerulosclerosis and reduced podocyte loss. In a ZSF1 rat model of diabetic kidney injury, therapy alone with NPR3i did not have beneficial effects on renal function\/histology, but when combined with losartan (angiotensin receptor blocker), NPR3i potentiated its ameliorative effects on albuminuria. In conclusion, these results suggest that NPR3 may contribute to kidney disease progression. <\/jats:p>","DOI":"10.1038\/s41598-024-61603-4","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T03:43:18Z","timestamp":1716522198000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Unraveling the role of natriuretic peptide clearance receptor (NPR3) in glomerular diseases"],"prefix":"10.1038","volume":"14","author":[{"given":"Dina","family":"Dabaghie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Charrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernilla","family":"Tonelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitta","family":"Rosengren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gizem","family":"Korkut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna B.","family":"Granqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaakko","family":"Patrakka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,24]]},"reference":[{"key":"61603_CR1","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S0140-6736(13)60439-0","volume":"382","author":"K-U Eckardt","year":"2013","unstructured":"Eckardt, K.-U. et al. Evolving importance of kidney disease: From subspecialty to global health burden. Lancet 382, 158\u2013169 (2013).","journal-title":"Lancet"},{"key":"61603_CR2","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.2215\/CJN.13791215","volume":"11","author":"AR Kitching","year":"2016","unstructured":"Kitching, A. R. & Hutton, H. L. The players: Cells involved in glomerular disease. Clin. J. Am. Soc. Nephrol. 11, 1664\u20131674 (2016).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"61603_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-68964-5_15","author":"LR Potter","year":"2009","unstructured":"Potter, L. R., Yoder, A. R., Flora, D. R., Antos, L. K. & Dickey, D. M. Natriuretic peptides: Their structures, receptors, physiologic functions and therapeutic applications. Handb. Exp. Pharmacol. https:\/\/doi.org\/10.1007\/978-3-540-68964-5_15 (2009).","journal-title":"Handb. Exp. Pharmacol."},{"key":"61603_CR4","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1681\/ASN.2015070731","volume":"28","author":"J Staffel","year":"2017","unstructured":"Staffel, J. et al. Natriuretic peptide receptor guanylyl cyclase-A in podocytes is renoprotective but dispensable for physiologic renal function. J. Am. Soc. Nephrol. JASN 28, 260\u2013277 (2017).","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"61603_CR5","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.2337\/db10-1181","volume":"60","author":"KI Woroniecka","year":"2011","unstructured":"Woroniecka, K. I. et al. Transcriptome analysis of human diabetic kidney disease. Diabetes 60, 2354\u20132369 (2011).","journal-title":"Diabetes"},{"key":"61603_CR6","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/cvr\/cvy224","volume":"115","author":"D Rahmutula","year":"2019","unstructured":"Rahmutula, D., Zhang, H., Wilson, E. E. & Olgin, J. E. Absence of natriuretic peptide clearance receptor attenuates TGF-\u03b21-induced selective atrial fibrosis and atrial fibrillation. Cardiovasc. Res. 115, 357\u2013372 (2019).","journal-title":"Cardiovasc. Res."},{"key":"61603_CR7","doi-asserted-by":"publisher","first-page":"6870","DOI":"10.1126\/scisignal.aam6870","volume":"10","author":"W Wu","year":"2017","unstructured":"Wu, W. et al. Enhancing natriuretic peptide signaling in adipose tissue, but not in muscle, protects against diet-induced obesity and insulin resistance. Sci. Signal. 10, 6870 (2017).","journal-title":"Sci. Signal."},{"key":"61603_CR8","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1161\/CIRCULATIONAHA.115.018622","volume":"133","author":"SA Hubers","year":"2016","unstructured":"Hubers, S. A. & Brown, N. J. Combined angiotensin receptor antagonism and neprilysin inhibition. Circulation 133, 1115\u20131124 (2016).","journal-title":"Circulation"},{"key":"61603_CR9","doi-asserted-by":"publisher","unstructured":"Neprilysin inhibitors: Emerging therapy for heart failure. Annu. Rev. Med. https:\/\/doi.org\/10.1146\/annurev-med-052915-015509.","DOI":"10.1146\/annurev-med-052915-015509"},{"key":"61603_CR10","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.lfs.2019.02.027","volume":"221","author":"V Malek","year":"2019","unstructured":"Malek, V., Sharma, N., Sankrityayan, H. & Gaikwad, A. B. Concurrent neprilysin inhibition and renin-angiotensin system modulations prevented diabetic nephropathy. Life Sci. 221, 159\u2013167 (2019).","journal-title":"Life Sci."},{"key":"61603_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002326","author":"E Uijl","year":"2019","unstructured":"Uijl, E. et al. Angiotensin-neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury. J. Hypertens. https:\/\/doi.org\/10.1097\/HJH.0000000000002326 (2019).","journal-title":"J. Hypertens."},{"issue":"133","key":"61603_CR12","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1042\/CS20180882","volume":"1979","author":"R Bijkerk","year":"2019","unstructured":"Bijkerk, R. et al. Neutral endopeptidase inhibitors blunt kidney fibrosis by reducing myofibroblast formation. Clin. Sci. Lond. Engl. 1979(133), 239\u2013252 (2019).","journal-title":"Clin. Sci. Lond. Engl."},{"key":"61603_CR13","doi-asserted-by":"publisher","first-page":"15095","DOI":"10.14814\/phy2.15095","volume":"9","author":"L Wang","year":"2021","unstructured":"Wang, L., Tang, Y., Buckley, A. F. & Spurney, R. F. Blockade of the natriuretic peptide clearance receptor attenuates proteinuria in a mouse model of focal segmental glomerulosclerosis. Physiol. Rep. 9, 15095 (2021).","journal-title":"Physiol. Rep."},{"key":"61603_CR14","doi-asserted-by":"publisher","first-page":"3542","DOI":"10.1016\/j.bmcl.2017.05.061","volume":"27","author":"N Nishizawa","year":"2017","unstructured":"Nishizawa, N. et al. A potent and selective natriuretic peptide receptor-3 blocker 11-mer peptide created by hybridization of musclin and atrial natriuretic peptide. Bioorg. Med. Chem. Lett. 27, 3542\u20133545 (2017).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"61603_CR15","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0960-894X(00)00387-5","volume":"10","author":"CA Veale","year":"2000","unstructured":"Veale, C. A. et al. The discovery of non-basic atrial natriuretic peptide clearance receptor antagonists. Part 1. Bioorg. Med. Chem. Lett. 10, 1949\u20131952 (2000).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"61603_CR16","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1038\/s41598-018-23104-z","volume":"8","author":"S Zambrano","year":"2018","unstructured":"Zambrano, S. et al. FYVE domain-containing protein ZFYVE28 regulates EGFR-signaling in podocytes but is not critical for the function of filtration barrier in mice. Sci. Rep. 8, 4712 (2018).","journal-title":"Sci. Rep."},{"key":"61603_CR17","doi-asserted-by":"publisher","first-page":"7403","DOI":"10.1073\/pnas.96.13.7403","volume":"96","author":"N Matsukawa","year":"1999","unstructured":"Matsukawa, N. et al. The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc. Natl. Acad. Sci. USA 96, 7403\u20137408 (1999).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"61603_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/8424502","volume":"2018","author":"MKE Ougaard","year":"2018","unstructured":"Ougaard, M. K. E. et al. Murine nephrotoxic nephritis as a model of chronic kidney disease. Int. J. Nephrol. 2018, 1\u201312 (2018).","journal-title":"Int. J. Nephrol."},{"key":"61603_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2021.108056","volume":"36","author":"X Zhang","year":"2022","unstructured":"Zhang, X., Zhou, Y. & Ma, R. Potential effects and application prospect of angiotensin receptor-neprilysin inhibitor in diabetic kidney disease. J. Diabetes Complic. 36, 108056 (2022).","journal-title":"J. Diabetes Complic."},{"key":"61603_CR20","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1681\/ASN.2011100985","volume":"23","author":"Y Ogawa","year":"2012","unstructured":"Ogawa, Y. et al. Natriuretic peptide receptor guanylyl cyclase-A protects podocytes from aldosterone-induced glomerular injury. J. Am. Soc. Nephrol. 23, 1198\u20131209 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"61603_CR21","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1111\/j.1742-4658.2011.08082.x","volume":"278","author":"LR Potter","year":"2011","unstructured":"Potter, L. R. Natriuretic peptide metabolism, clearance and degradation: Natriuretic peptide metabolism. FEBS J. 278, 1808\u20131817 (2011).","journal-title":"FEBS J."},{"key":"61603_CR22","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1172\/JCI113926","volume":"83","author":"AS Hollister","year":"1989","unstructured":"Hollister, A. S. et al. Clearance of atrial natriuretic factor by lung, liver, and kidney in human subjects and the dog. J. Clin. Invest. 83, 623\u2013628 (1989).","journal-title":"J. Clin. Invest."},{"key":"61603_CR23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/nrcardio.2016.200","volume":"14","author":"C Dj","year":"2017","unstructured":"Dj, C. Long-term neprilysin inhibition\u2014Implications for ARNIs. Nat. Rev. Cardiol. 14, 171\u2013186 (2017).","journal-title":"Nat. Rev. Cardiol."},{"key":"61603_CR24","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1046\/j.1523-1755.1999.00393.x","volume":"55","author":"N Ardaillou","year":"1999","unstructured":"Ardaillou, N., Placier, S., Striker, L., Striker, G. & Ardaillou, R. Mesangial cells from diabetic NOD mice constitutively express increased density of atrial natriuretic peptide C receptors. Kidney Int. 55, 1293\u20131302 (1999).","journal-title":"Kidney Int."},{"key":"61603_CR25","doi-asserted-by":"crossref","unstructured":"Zhou, H. & Murthy, K. S. Identification of the G protein-activating sequence of the single-transmembrane natriuretic peptide receptor C (NPR-C). Am. J. Physiol.-Cell Physiol. 284, C1255\u2013C1261 (2003).","DOI":"10.1152\/ajpcell.00520.2002"},{"key":"61603_CR26","doi-asserted-by":"publisher","first-page":"21835","DOI":"10.1038\/s41598-021-01095-8","volume":"11","author":"T Handa","year":"2021","unstructured":"Handa, T. et al. Osteocrin ameliorates adriamycin nephropathy via p38 mitogen-activated protein kinase inhibition. Sci. Rep. 11, 21835 (2021).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-61603-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-61603-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-61603-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T03:43:45Z","timestamp":1716522225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-61603-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["61603"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-61603-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,24]]},"assertion":[{"value":"4 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EC,\u00a0PT, BR, ABG and ML are\/were employed by AstraZeneca. JP\u2019s research lab is financially supported by AstraZeneca. JP\u00a0is employed by Unilabs.\u00a0All other authors have no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11850"}}